Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for(2)
时间:2019-05-26 13:11 来源:百度新闻 作者:巧天工 点击:次
AUSTIN, Texas, April 01, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that updated Phase 1/2 data for pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D) will be presented in an oral presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD) held in Bellevue, Washington, April 6-9. The Company will host a conference call at 8:30 a.m. ET on Monday, April 8. SIMD Oral Presentation Title:Sustained Reductions in Plasma Arginine Following Pegzilarginase Administration in Patients with Arginase-1 Deficiency are Accompanied by Improvements in Mobility and Adaptive Behavior Presentation Date:Sunday, April 7, 4:00 p.m. PT Location:Hyatt Regency, Bellevue, WA Presenter:George Diaz, M.D., Ph.D., Icahn School of Medicine at Mt. Sinai, New York, NY An electronic version of the presentation will be available for download on thePresentations & Eventssection of the Companys investor relations website after the conference. Clinical Update Conference Call & Webcast Details Aeglea will hold a conference call on Monday, April 8, 2019 at 8:30 a.m. ET. To access the live conference call via phone, please dial (877) 709-8155 (toll free) withinthe United States,or (201) 689-8881 internationally. A replay of the call will be available throughApril 15, 2019by dialing (877) 660-6853 withinthe United Statesor (201) 612-7415 internationally. The conference ID is 13689004. To access the live and archived webcast of the presentation, please visit thePresentations & Eventssection of the Aeglea BioTherapeuticsinvestor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. About Aeglea BioTherapeutics Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit About Pegzilarginase in Arginase 1 Deficiency Pegzilarginase is an enhanced human arginase that enzymatically depletes the amino acid arginine. Aeglea is developing pegzilarginase for the treatment of patients with Arginase 1 Deficiency, a rare debilitating disease presenting in childhood with persistent hyperargininemia, severe progressive neurological abnormalities and early mortality. Pegzilarginase is intended for use as an enzyme replacement therapy in patients to reduce elevated blood arginine levels. Aegleas interim Phase 1/2 data demonstrated clinical improvements and rapid and sustained lowering of plasma arginine in Arginase 1 Deficiency patients. The Company intends to initiate its single, global pivotal Phase 3 PEACE trial designed to assess the effects of treatment with pegzilarginase versus placebo over 24 weeks with a primary endpoint of plasma arginine reduction. Safe Harbor / Forward-Looking Statements (责任编辑：波少) |